<DOC>
	<DOCNO>NCT02151253</DOCNO>
	<brief_summary>The objective study evaluate armodafinil wakefulness-promoting therapy mean improve residual daytime sleepiness patient treat nocturia .</brief_summary>
	<brief_title>Cross-over Study Armodafinil Treatment Daytime Sleepiness Associated With Treated Nocturia</brief_title>
	<detailed_description />
	<mesh_term>Nocturia</mesh_term>
	<mesh_term>Armodafinil</mesh_term>
	<mesh_term>Modafinil</mesh_term>
	<criteria>1 . Receiving standardofcare therapy nocturia base assessment study physician 2 . Evaluation study physician indicate patient meet criteria either overactive bladder diagnosis , nocturnal polyuria diagnosis . 3 . Mean number nocturia episodes least 2 per night base day sleep/bladder diary 4 . Epworth Sleepiness Scale Score least 10 5 . Clinical Global Impression Sleepiness least Moderate 6 . Age 1890 year inclusive 1 . Medications affect urinary sleepwake function therapy OAB NP within 5 halflives baseline assessment 2 . Sleep disorder nocturia base history screen assessment 3 . Unstable medical psychiatry condition 4 . Medical psychiatric condition affect sleep/wake urologic function 5 . ApneaHypopnea Index ( AHI ) ≥ 15 screen polysomnogram 6 . Periodic Leg Movement Arousal Index ( PLMAI ) ≥ 15 screen polysomnogram 7 . History substance abuse dependence last year 8 . Regular consumption 800 mg caffeine use 9 . Shiftwork 3 month prior study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Nocturia</keyword>
	<keyword>Daytime sleepiness</keyword>
</DOC>